



Clinical trial results:

A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascular risk in GH deficient adults

Summary

EudraCT number	2004-004835-72
Trial protocol	GB
Global end of trial date	23 October 2013

Results information

Result version number	v1 (current)
This version publication date	28 August 2020
First version publication date	28 August 2020
Summary attachment (see zip file)	Summary 2004-004835-72 (EudraCT study letter 18.09.19.pdf)

Trial information

Trial identification

Sponsor protocol code	RG_05-161
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	University of Birmingham
Sponsor organisation address	Edgbaston, Birmingham, United Kingdom, B15 2TT
Public contact	Research Governance Team, University of Birmingham, researchgovernance@contacts.bham.ac.uk
Scientific contact	Research Governance Team, University of Birmingham, researchgovernance@contacts.bham.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 October 2013
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	23 October 2013
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To determine the impact of growth hormone replacement therapy on quality of Life in adults with severe growth hormone deficiency

Protection of trial subjects:

Inclusion criteria:

Aged over 18

Able to provide informed consent

Severe GH deficiency in adult life

No GH replacement therapy for six months

Other hormone replacement therapy stable over previous six months

Life expectancy >15 months

Exclusion criteria:

Active malignant disease

Active Cushings disease or acromegaly

Pregnancy

Proliferative diabetic retinopathy

Sensitivity to GH or its preservative

Breast feeding

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 May 2005
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 88888
Worldwide total number of subjects	88888
EEA total number of subjects	88888

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	88888

Subject disposition

Recruitment

Recruitment details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

Pre-assignment

Screening details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

Arms

Arm title	Overall
-----------	---------

Arm description:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

Arm type	n/a
Investigational medicinal product name	Growth Hormone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

Number of subjects in period 1	Overall
Started	88888
Completed	88888

Baseline characteristics

Reporting groups

Reporting group title	Overall
-----------------------	---------

Reporting group description:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

Reporting group values	Overall	Total	
Number of subjects	88888	88888	
Age categorical			
After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.			
Units: Subjects			
Not applicable	88888	88888	
Gender categorical			
After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.			
Units: Subjects			
Not applicable	88888	88888	

End points

End points reporting groups

Reporting group title	Overall
Reporting group description: After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.	

Primary: Not applicable

End point title	Not applicable ^[1]
End point description: After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.	
End point type	Primary
End point timeframe: After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain.	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses have been specified as the trial was terminated early. After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	88888 ^[2]			
Units: n/a	88888			

Notes:

[2] - 88888 is referring to not applicable due to the data integrity issues.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	n/a
Dictionary version	0

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No adverse events have been specified as the trial was terminated early. After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain.

Notes: